Loading company
Phio Pharmaceuticals Corp.
PHIO · Nasdaq · ·
$1.03-1.0%Sep 29 close
- 1M
- -8.8%
- 6M
- -14.2%
- 1Y
- -58.5%
- 5Y
- -99.5%
PHIO · Nasdaq · ·
$1.03-1.0%Sep 29 close
The quarter ending December 31, 2020, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2020 | 3 months toDec 31, 2019 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$4.1M | -$2.2M | -91.04% |
| Profit per share | -$0.45 | -$1.48 | +69.59% |
| Free Cash Flow | -$4M | -$2.5M | -58.67% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Phio Pharmaceuticals Corp. has no earnings call transcript available.
“We realized significant headway on foundational building blocks advancing the PH-762 development program during the 2 nd quarter,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company’s website, www.phiopharma.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Phio Pharmaceuticals Corp.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.